e-learning
resources
London 2016
Wednesday, 07.09.2016
IPF treatment II
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Clinical experience with nintedanib for IPF in 3 UK tertiary referral centres
Hannah Toellner (Burntisland, United Kingdom), Hannah Toellner, W. Beswick, M.G. Crooks, C. Donaldson, I. Forrest, S.P. Hart, C. Leonard, M. Major, A.J. Simpson, N. Chaudhuri
Source:
International Congress 2016 – IPF treatment II
Session:
IPF treatment II
Session type:
Oral Presentation
Number:
4961
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Hannah Toellner (Burntisland, United Kingdom), Hannah Toellner, W. Beswick, M.G. Crooks, C. Donaldson, I. Forrest, S.P. Hart, C. Leonard, M. Major, A.J. Simpson, N. Chaudhuri. Clinical experience with nintedanib for IPF in 3 UK tertiary referral centres. Eur Respir J 2016; 48: Suppl. 60, 4961
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Clinical profile of pulmonary hypertension at a tertiary care centre, India
Source: International Congress 2017 – Imaging and lung disease PH
Year: 2017
Variability in access and referral to pulmonary rehabilitation in European bronchiectasis patients enrolled in the EMBARC registry
Source: International Congress 2018 – Latest advances in pulmonary rehabilitation assessment and content
Year: 2018
Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry
Source: Eur Respir J 2015; 46: 186-196
Year: 2015
IPF Care, a support program for patients with idiopathic pulmonary fibrosis in the UK
Source: International Congress 2015 – Latest insights into chronic care
Year: 2015
Clinical characteristics of patients with Idiopathic pulmonary fibrosis in a tertiary care center of a developing country
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
What proportion of patients with Idiopathic Pulmonary Fibrosis fall outside UK prescribing criteria for anti-fibrotic treatment? A UK specialist centre review.
Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Year: 2019
Selected clinical highlights from the 2012 ERS congress in Vienna
Source: Eur Respir J 2013; 41: 1219-1227
Year: 2013
Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain.
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Frequency of chronic pulmonary aspergillosis in patients treated for pulmonary tuberculosis at a tertiary care hospital in Karachi, Pakistan.
Source: Virtual Congress 2021 – Tuberculosis, COVID-19 and other comorbidities
Year: 2021
Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015
Pulmonary nocardiosis in renal transplant patients in a tertiary care hospital in Pakistan
Source: Virtual Congress 2020 – Aspergillosis and chronic lung infections
Year: 2020
Management of idiopathic pulmonary fibrosis in France: A survey of 1,456 pulmonologists
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Safety and tolerability of immunosuppression in non-IPF ILD: clinical experience from a tertiary ILD centre.
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019
Pulmonary aspergillous; clinical features and outcomes in a tertiary care hospital
Source: International Congress 2015 – Immunodepression and severe pneumonia
Year: 2015
Clinical findings at initial presentation of IPF patients at a university hospital referral center
Source: International Congress 2014 – ILDs 5
Year: 2014
Differing clinical courses of IPF at an acute district general hospital
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Idiopathic pulmonary fibrosis and systemic sclerosis-interstitial lung disease: features at admission to a tertiary pulmonology unit.
Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020
Acute exacerbation of ILD: an Indian tertiary centre experience
Source: International Congress 2018 – Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment
Year: 2018
Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early single centre Irish experience
Source: Annual Congress 2012 - Diffuse parenchymal lung disease III
Year: 2012
Do tertiary paediatric hospitals deal with the same spectrum of paediatric pulmonary hypertension as multicentre registries?
Source: Eur Respir J 2013; 41: 236-239
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept